Vimarsana
Biggest News Aggregation in the World

Quincy Chu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Quincy Chu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Quincy Chu Today - Breaking & Trending Today

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers - Vimarsana News

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers

/PRNewswire/ -- Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug...

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers - Vimarsana News

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers

/PRNewswire/ -- Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug...

Health Canada Approves OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma - Vimarsana News

Health Canada Approves OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

/CNW Telbec/ - Today, Bristol Myers Squibb Canada (BMS) announced Health Canada's approval of OPDIVO® (nivolumab) 360 mg every three weeks or 3mg/kg every two...

Health Canada Approves OPDIVO® plus YERVOY® as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma - Vimarsana News

Health Canada Approves OPDIVO® plus YERVOY® as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

First new systemic therapy in more than 15 years for cancer related to asbestos exposure  Today, Bristol Myers Squibb Canada announced Health Canada's approval of OPDIVO ® 360 mg every three weeks or 3mgkg every two weeks plus YERVOY ® 1 mgkg every six weeks for the treatment of adult patients with unresectable malignant pleural mesothelioma who have not received prior systemic therapy for MPM. i This is the ...